Journal
AMERICAN JOURNAL OF THERAPEUTICS
Volume 22, Issue 4, Pages 298-317Publisher
LIPPINCOTT WILLIAMS & WILKINS
DOI: 10.1097/MJT.0000000000000103
Keywords
cyclodextrins; sugammadex; rocuronium; vecuronium; muscle relaxant; muscle relaxant reversal; selective relaxant binding agents
Categories
Funding
- Organon
- Schering/Plough
- Merck
Ask authors/readers for more resources
Although neuromuscular block (NMB) allows immobility for airway management and surgical exposure, termination of its effect is limited by and associated with side effects of acetylcholinesterase inhibitors. Sugammadex is a selective relaxant binding agent that has been shown to reverse deep NMB, even when administered 3 minutes following a 1.2 mg/kg dose of rocuronium. This novel drug is a modified gamma cyclodextrin, that through encapsulation process terminates the effects of rocuronium and vecuronium (aminosteroid muscle relaxants), and enables the anesthesiologists rapidly to reverse profound NMB induced by rocuronium or vecuronium, in a can't ventilate, can't intubate crisis. In this review, data from published phase 1, 2, and 3 clinical trials are reviewed and presented. In addition, clinical trials on special patient populations (patients with pulmonary disease and renal insufficiency) are evaluated. Each article reviewed will conclude with a discussion of relevance, focus on adverse event profile, and clinical usefulness.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available